J Bone Metab.
2022 Nov;29(4):217-223. 10.11005/jbm.2022.29.4.217.
The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
- Affiliations
-
- 1Division of Endocrinology, Agamenon Magalhães Hospital, University of Pernambuco Medical School, Recife, Brazil
- 2Fleury Diagnostics, Recife, Brazil
- 3Division of Endocrinology and Diabetes, FBandeira Endocrine Institute, Agamenon Magalhães Hospital, University of Pernambuco Medical School, Recife, Brazil
- KMID: 2536843
- DOI: http://doi.org/10.11005/jbm.2022.29.4.217
Abstract
- Denosumab is a potent anti-resorptive medication used to treat patients at high risk for osteoporosis; however, its beneficial effects on the skeletal system are quickly reversed after discontinuation. In contrast, bisphosphonates (BPs) are anti-resorptive agents with residual effects on the bone matrix; thus, these are capable of preserving bone mass for a long time. Therefore, subsequent anti-resorptive treatment with BPs is mandatory to prevent rebound fractures. Furthermore, BP administration before denosumab treatment appears to be a reasonable strategy for reducing hyperactivation of bone remodeling. In this review, we summarize the effects of BP administration before denosumab treatment in preventing rebound fractures after denosumab discontinuation.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
- Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
- Medication Use Evaluation of Denosumab in Postmenopausal Women with Osteoporosis or Osteopenia
- Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
- Pharmacologic treatment of osteoporosis
